Professor Colin Dayan and Professor John Gregory of Cardiff University, with support from the Diabetes Research Unit Cymru and the Swansea Trials Unit, have recently received funding for a five-year study to evaluate the utility of a monoclonal antibody (ustekinumab), licensed for use in the treatment of psoriasis and Crohn's disease, as a means of preserving insulin producing cells in young people with recent onset type I diabetes.
The study has been funded by the Efficacy and Mechanism Evaluation (EME) programme a partnership between the MRC and NIHR, with contributions from the Chief Scientist Office (CSO) in Scotland, Health and Care Research Wales and the HSC R&D Division, Public Health Agency in Northern Ireland. It is the funding contribution from Health and Care Research Wales that opens the EME programme to researchers based in Wales.
Across the UK there are approximately 3000 people a year diagnosed with new onset type I diabetes with over half of them being young people and children under the age of eighteen.
The study - USTEKID - will be carried out across the UK utilising, amongst others, the network of experts and facilities that make up the Type 1 Diabetes UK Immunotherapy Consortium.
A video aimed at explaining the study to young people in everyday terms and designed to encourage them to participate in the study is now being finalised.
If you would like more details concerning this trial, contact Dr Kym Thorne, USTEKID trial manager at email@example.com.